Breast Cancer Liquid Biopsy Market – By Circulating Biomarkers, By Product , By Application , By End User , By Geography - Opportunity Analysis & Industry Forecast, 2024-2030

Breast Cancer Liquid Biopsy Breast Cancer Market Overview:

Breast Cancer Liquid Biopsy Market size is expected to be valued at $1.7 billion by the end of the year 2030 and is set to grow at a CAGR of 21.8% during the forecast period from 2024-2030. The breast cancer liquid biopsy market is experiencing rapid growth, driven by the increasing prevalence of breast cancer, increasing preference of non-invasive procedures, advancements in technological capabilities and increasing breast cancer awareness programs. Liquid biopsy offers a non-invasive approach to cancer detection and monitoring, providing valuable insights into tumor biology through the analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). This innovative technology enables earlier disease detection, real-time assessment of treatment efficacy, and the development of tailored treatment plans. While challenges such as standardization and assay sensitivity persist, the overall market trajectory is positive, with significant potential to improve patient outcomes.

The liquid biopsy market is at the forefront of medical innovation, heralding a new era of precision medicine. By analyzing circulating biomarkers in bodily fluids, primarily blood, liquid biopsy offers a non-invasive alternative to traditional tissue biopsies. Precision oncology, a specialized application of personalized medicine, is revolutionizing the breast cancer liquid biopsy market. By focusing on identifying unique molecular targets within tumors, precision oncology has spurred a significant demand for biopsies capable of accurately capturing and analyzing these critical biomarkers. Also, the surge in funding for minimally invasive cancer diagnostics is largely attributed to the rapid advancements in liquid biopsy technology. investors are recognizing the immense potential of liquid biopsy and pouring significant resources into research and development to bring these technologies to market. MiRXES secured $50 million in Series D funding in July 2023 to develop liquid biopsy products for colorectal cancer and early cancer detection. Concurrently, Epic Sciences raised $24 million in Series G funding in April 2023 to focus on liquid biopsy solutions for metastatic breast cancer. These funding rounds underscore the growing interest and investment in liquid biopsy as a promising diagnostic tool.

Market Snapshot: 
--

Liquid Biopsy Breast Cancer Market - Report Coverage:

The “Liquid Biopsy Breast Cancer Market Report - Forecast (2024-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Liquid Biopsy Breast Cancer Market.

COVID-19 / Ukraine Crisis - Impact Analysis:  

1. The global focus on the COVID-19 pandemic led to disruptions in healthcare systems, including delayed cancer screenings and a shift in resource allocation. Consequently, the diagnosis and management of breast cancer, including the adoption of liquid biopsy were affected. The increased awareness of early disease detection and the accelerated pace of research in diagnostics contributed to a growing interest in liquid biopsy technologies
2. The Russia-Ukraine conflict indirectly impacted the breast cancer liquid biopsy market. The availability of research funding and talent acquisition have been affected slowing down advancements in liquid biopsy technology. 

Key Takeaways:

North America Dominates the Market

In North America, particularly the United States, the high prevalence of cancer, including breast cancer, is met with substantial healthcare investment. The U.S. has one of the highest healthcare spending rates per capita globally, which supports the adoption of innovative diagnostic tools like liquid biopsies. This spending includes funding for research, development, and the implementation of advanced technologies in clinical settings. In 2023, healthcare expenditure in North America was substantial, with the United States and Canada investing heavily in their healthcare systems. According to the Centers for Medicare & Medicaid Services (CMS), the U.S. spent approximately $4.3 trillion on healthcare, representing about 18.3% of the country's GDP and anticipates reaching approximately $4.5 trillion in 2024. This high level of spending underscores the nation's commitment to advanced medical technologies and comprehensive care that supports a robust healthcare system, facilitating access to advanced diagnostic tools and treatments. Similarly, the Canadian Institute for Health Information (CIHI) reported that Canada’s healthcare expenditure was roughly 11.5% of its GDP in 2023 and forecasts an increase of 3.5% in Canada’s healthcare expenditure, which is expected to reach approximately US$230 billion. This rise reflects continued investments in healthcare services and innovations, supporting advancements in diagnostic and treatment technologies. The region's supportive regulatory environment, exemplified by the FDA’s efficient approval processes, further facilitates the rapid market introduction of new technologies. Combined with a competitive market presence, favorable funding, and reimbursement policies, North America is well-positioned to sustain its leadership in the breast cancer liquid biopsy market.

Circulating Tumor DNA is the Largest Segment

Circulating Tumor DNA (ctDNA) is currently the dominant type of biomarker in the liquid biopsy market. ctDNA can be detected in very small quantities, allowing for early cancer detection and can provide information about various aspects of the tumor, including mutations, copy number variations, and methylation patterns. It has gained significant traction due to its sensitivity, versatility, and the advancements in sequencing technologies have significantly improved the ability to detect and analyze ctDNA. In March 2023, Reveal Genomics, S.L., a Barcelona-based biotechnology start-up seeking to revolutionize precision oncology through biomarker innovation, announced a new addition to its pipeline consisting of a novel biomarker approach in liquid biopsy for patients with advanced cancer. Reveal Genomics machine learning-based technology applied to ctDNA was able to predict drug response and survival outcome in patients with metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitors.

Reference Laboratories Lead the Market 

Reference laboratories ie specifically the pathology services, are currently the predominant players in the breast cancer liquid biopsy market. These Laboratories are referred as the Backbone of Breast Cancer Liquid Biopsy. These laboratories offer a comprehensive range of tests, including histopathology, cytology, immunohistochemistry, molecular pathology, and flow cytometry, to support accurate diagnosis, treatment planning, and disease monitoring. Their expertise in handling complex samples and utilizing advanced technologies is instrumental in improving patient outcomes. While hospitals and physician offices are progressively incorporating liquid biopsy into their diagnostic offerings, reference laboratories continue to hold a substantial market share due to their comprehensive expertise and capacity for complex testing. In June 2023, X-ZELL formed a partnership with Germany-based MVZ for pathology to utilize cryoimmunostaining technology in the treatment of early-stage prostate cancer.

Adoption of Non-invasive Diagnostic Techniques

The adoption of non-invasive diagnostic techniques, particularly liquid biopsy, is rapidly gaining traction in the breast cancer landscape. Traditional methods like mammograms and tissue biopsies, while effective, often involve invasive procedures that can cause discomfort and anxiety. Liquid biopsy offers a less invasive alternative by analyzing circulating biomarkers, such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), in blood samples. This approach enables earlier detection, real-time monitoring of disease progression, and personalized treatment plans. This approach offers a significant advantage over traditional invasive methods by providing a dynamic view of tumor progression without subjecting patients to the risks and discomfort associated with tissue biopsies. While challenges such as standardization and sensitivity remain, ongoing research and technological advancements are steadily improving the clinical utility of liquid biopsy in breast cancer management. In May 2023, aiGENE secured funding from the Colorado Office of Economic Development and International Trade (OEDIT) to develop a liquid biopsy product capable of detecting multiple types of cancer at an early stage and monitoring disease progression.

Standardization and Reproducibility

While the technology has shown great promise, there is a lack of standardized protocols for sample collection, processing, and analysis. Despite advancements in technology, isolating and analyzing these biomarkers from a complex biological background can be difficult. Factors such as low tumor burden, the presence of background cfDNA, and the heterogeneity of CTCs contribute to this challenge. False-negative results can lead to misdiagnosis or delayed treatment, while false-positive results can cause unnecessary anxiety and invasive procedures. This variability between laboratories can lead to inconsistent results and hinder the adoption of liquid biopsy as a routine diagnostic tool. Overcoming this challenge requires collaborative efforts to develop standardized operating procedures and quality control measures to ensure reliable and comparable results across different testing centers.     

For more details on this report - Request for Sample

Key Market Players: 

Product/Service launches, approvals, patents and events, acquisitions, partnerships, and collaborations are key strategies adopted by players in the Liquid Biopsy Breast Cancer Market. The top 10 companies in this industry are listed below:

1. Qiagen
2. Thermo Fisher Scientific
3. Bio-Rad Laboratories Inc.
4. Guardant Health Inc
5. NeoGenomics Laboratories
6. F. Hoffmann-La Roche Ltd
7. Myriad Genetics, Inc
8. Angle PLC
9. Sysmex Corporation
10. Illumina Inc.

Scope of the Report: 

For more Lifesciences and Healthcare Market reports, please click here